Genome-wide association studies (GWAS) have identified many risk loci for complex diseases, but effect sizes are typically small and information on the underlying biological processes is often lacking. Associations with metabolic traits as functional intermediates can overcome these problems and potentially inform individualized therapy. Here we report a comprehensive analysis of genotype-dependent metabolic phenotypes using a GWAS with non-targeted metabolomics. We identified 37 genetic loci associated with blood metabolite concentrations, of which 25 show effect sizes that are unusually high for GWAS and account for 10-60% differences in metabolite levels per allele copy. Our associations provide new functional insights for many disease-related associations that have been reported in previous studies, including those for cardiovascular and kidney disorders, type 2 diabetes, cancer, gout, venous thromboembolism and Crohn's disease. The study advances our knowledge of the genetic basis of metabolic individuality in humans and generates many new hypotheses for biomedical and pharmaceutical research.
Genome-wide association studies (GWAS) have identified many risk loci for complex diseases, but effect sizes are typically small and information on the underlying biological processes is often lacking. Associations with metabolic traits as functional intermediates can overcome these problems and potentially inform individualized therapy. Here we report a comprehensive analysis of genotype-dependent metabolic phenotypes using a GWAS with non-targeted metabolomics. We identified 37 genetic loci associated with blood metabolite concentrations, of which 25 show effect sizes that are unusually high for GWAS and account for 10-60% differences in metabolite levels per allele copy. Our associations provide new functional insights for many disease-related associations that have been reported in previous studies, including those for cardiovascular and kidney disorders, type 2 diabetes, cancer, gout, venous thromboembolism and Crohn's disease. The study advances our knowledge of the genetic basis of metabolic individuality in humans and generates many new hypotheses for biomedical and pharmaceutical research.
Understanding the role of genetic predispositions and their interaction with environmental factors in complex chronic diseases is key to the development of safe and efficient therapies, to diagnosis and to prevention. GWAS have identified hundreds of disease-risk loci 1 ; however, functional information on the underlying biological processes is often lacking 2 . Previously, we have shown the promise of using associations with blood metabolites as functional intermediate phenotypes (socalled genetically determined metabotypes (GDMs)) to understand the potential relevance of genetic variants for biomedical and pharmaceutical research 3, 4 . Building on this previous work, we present here the most comprehensive evaluation of genetic variance in human metabolism so far, combining genetics and metabolomics for hypothesis generation in a GWAS. We used an extensive, non-targeted and metabolome-wide panel of small molecules, analysing .250 metabolites from 60 biochemical pathways in serum samples from 2,820 individuals from two large population-based European cohorts. We identified 37 genetic loci that were significant at a stringent genome-wide threshold. In contrast to most GWAS, these loci showed exceptionally large effect sizes of 10-60% per allele copy in 25 loci. In the majority of cases, a protein that is biochemically related to the associated metabolic traits is encoded at these loci. As a proof-of-principle validation of new discoveries, we experimentally validated the predicted function of SLC16A9 as a carnitine efflux transporter. We further cross-referenced these loci with databases of disease-related and pharmaceuticallyrelevant genetic associations, uncovering hitherto unknown links and providing new hypotheses for the functions of these loci. We have made a knowledge-base resource publically available via a web-server to aid future functional studies, and biological as well as clinical interpretation of GWAS findings. This study provides compelling evidence for novel associations of metabolic traits with a wide range of loci of biomedical and pharmaceutical interest, and indicates a powerful new paradigm for dissecting human metabolic and disease pathways.
(n 5 1,052), using ultrahigh-performance liquid-phase chromatography and gas-chromatography separation, coupled with tandem mass spectrometry [5] [6] [7] . We achieved highly efficient profiling (24 min per sample) with low median process variability (,12%) of more than 250 metabolites, covering more than 60 biochemical pathways of human metabolism (Supplementary Table 1 ). On the basis of our previous observation that ratios between metabolite concentrations can strengthen the association signal and provide new information about possible metabolic pathways 4, 8 , we included all pairs of ratios between these metabolites in the genome-wide statistical analysis. To reduce the computational and data-storage burden associated with meta-analysing more than 37,000 metabolites and ratios, we applied a staged approach for selection of promising association signals ( Supplementary Fig. 1 ). In the initial screening stage, we assessed the association of approximately 600,000 genotyped single nucleotide polymorphisms (SNPs) with more than 37,000 metabolic traits (concentrations and their ratios) by fitting linear models separately in both cohorts to log-transformed metabolic traits and adjusting for age, gender and family structure ( Supplementary Fig. 2 and Supplementary Table 2 ). Next, we selected all association signals showing suggestive evidence of association with a metabolic trait in both cohorts (P , 10 26 in both cohorts, or P , 10 23 in one and P , 10 29 in the other). For each of these loci, we then reassessed the association signals through fixed-effects inverse variance meta-analysis of the two cohorts for all 37,000 available traits, using imputed SNPs relative to HapMap2 data (see Methods for details). The combination of SNP and trait that yielded the smallest P value in this meta-analysis was finally selected for each locus. To account for multiple testing, we applied conservative Bonferroni correction, leading to an adjusted threshold for genomewide significance of P , 2.0 3 10
212
.
Study results
We identified 37 independent loci that reached genome-wide significance in the meta-analysis (Table 1 and Supplementary Tables 3 and  4) . Twenty-three of these loci describe new genetic associations with metabolic traits, and 14 replicate and extend our knowledge of known GDMs, including 10 from our own studies 3, 4 . We used information on the locations of SNPs in genes, on known gene functions and on regional association plots ( Supplementary Fig. 2 ) to prioritize plausible candidate genes within associated loci. In most cases, our annotation was further supported by a statistical analysis of the association of gene relationships in published literature 9 (Supplementary Table 5 ). Associations with additional metabolic traits at the 37 loci presented in Table 1 may capture  further biochemical information, and are provided as Supplementary  Table 6 . At 30 loci, the sentinel SNP mapped to a protein that was biochemically linked to the associating metabolites, for instance because it was responsible for their synthesis, degradation or metabolism. Next, we searched literature and databases extensively (see web links in Methods) to identify which of these 37 loci were previously reported as being associated with a clinical endpoint, a medically relevant intermediate phenotype, or a pharmacogenetic effect. Associations of metabolites with disease loci can be used to gain novel information about possible metabolic changes associated with biological processes underlying that association (Fig. 1 , Table 1 and Supplementary Table 7) . In 15 cases, such a relationship could be identified on the basis of an association of the lead SNP or a proxy (r 2 $ 0.8) with the disease-associated SNPs, including those for cardiovascular disease, kidney disease, Crohn's disease, gout, cancer, adverse reactions to drug therapy and predisposing risk factors for diabetes and cardiovascular disease. In all except three loci, the SNPs are common, with minor allele frequencies greater than 10%. In 25 cases, the effect size per allele copy is larger than 10%, and up to 60% in the case of the acyl-CoA dehydrogenase (ACADS) locus.
Overlap with chronic disease loci
Many genetic-risk loci for heart disease, kidney failure, diabetes and other complex disorders have been identified by GWAS. However, the aetiology of these common diseases is complex and testable hypotheses are needed to develop new avenues for diagnosis and therapy. Associations of known disease-risk loci with metabolic traits allow the identification of new and potentially relevant biological processes and pathways. Here we report some examples from our study that illustrate this idea. The full association data set is freely available for further analysis and reference at http://www.gwas.eu.
Detoxification and kidney failure
N-acetylation is an important mechanism to detoxify nephrotoxic medications and environmental toxins. A reduced ability to detoxify such substances could lead to impaired kidney function. A key GDM is the N-acetyltransferase 8 (NAT8) locus, which was reported to associate with kidney function 10, 11 . Here we found a highly significant association of variation at the NAT8 locus with N-acetylornithine. Using this information, we investigated whether N-acetylornithine concentrations were associated with kidney function. In both our studies, we found a clear association with estimated glomerular filtration rate (eGFR), whereby higher levels of N-acetylornithine were correlated with lower eGFR (P KORA 5 7.6 3 10
24
, P TwinsUK 5 3.6 3 10 28 after adjusting for age and gender). In accord with the genetic effect of the NAT8 polymorphism in chronic kidney disease (CKD), the risk allele identified here was associated with higher N-acetylornithine concentrations. Although causality cannot be inferred from this kind of association study, the role of ornithine acetylation in the aetiology of CKD warrants further exploration.
Diabetes
Glucokinase (hexokinase 4) regulator (GCKR) is a major pleiotropic risk locus associated with diabetes-and cardiometabolic-related traits, such as fasting glucose and insulin levels 12 , triglyceride levels 13 and CKD 11 . Here we identified a highly significant association of this locus with mannose:glucose ratios. The fasting level of mannose is lower in carriers of the risk allele, as opposed to glucose being higher. Notably, we also observed a 3.3% increase in lactate concentration per copy of the risk allele at the same locus. Little is known about the physiological role of mannose, other than its use in protein glycosylation. Mannose enters the cell via a specific transporter that is insensitive to glucose 14 , and hepatic glycogen breakdown is implicated in the maintenance of plasma mannose concentrations 15 . These observations and the association with GCKR observed here, which is even stronger than that of glucose with GCKR, indicate a need for further investigation of the role of mannose as a differential biomarker, or even as a point of intervention in diabetes care.
Venous thromboembolism
With the mass-spectrometry method used here, different forms of the abundant fibrinogen A-a peptides can be detected. Fibrinogen has a role in the formation of blood clots. Its active form, the fibrinogen A-a chain ADSGEGDFXAEGGGVR, can be phosphorylated at serine 3 to ADpSGEGDFXAEGGGVR 16 . The ratio between the concentrations of these fibrinogen A-a peptides provides a measure for fibrinogen A-a phosphorylation (FAaP). Increased levels of FAaP have been observed under various physiological and pathophysiological conditions 17 . Here, three loci (ABO, ALPL and FUT2) associated with FAaP. Notably, these three genes are functionally linked: ABO (encoding ABO blood group (transferase A, a-1-3-N-acetylgalactosaminyltransferase; transferase B, a-1-3-galactosyltransferase)) and FUT2 (encoding fucosyltransferase 2) are involved in determining the blood group, and the ABO locus is associated with blood levels of the alkaline phosphatase ALPL 18 . The association of ALPL with FAaP may be explained either by a genotypedependent dephosphorylation of fibrinogen by ALPL, or by a genotypedependent change in the phosphorus pool available for FAaP. Variants in the ABO gene are associated with many different outcomes, including venous thromboembolism (VTE) 19 . The association of ABO with FAaP, and thus with modified blood coagulation properties, provides a ARTICLE RESEARCH 
Coronary artery disease
We have shown previously 4 that strong associations with metabolic traits, derived from GWAS, can point to interesting associations with clinical endpoints that would not otherwise be considered relevant. A recent meta-analysis with lipid traits 20 , using a similar strategy, identified several genetic loci that were found to affect the risk of coronary artery disease (CAD) in the CARDIoGRAM study 21 . Six of these loci are also reported here (ABO, NAT2, CPS1, NAT8, ALPL and KLKB1), although some of them showed only weak evidence for association with CAD (P , 0.01) in the CARDIoGRAM study (Supplementary The metabolic trait with the strongest association at the discovery stage in both studies is reported, together with the SNP identifier and the P value of association from the meta-analysis. Full association data are available in Supplementary Tables 3 & 5 and at http://www.gwas.eu. The loci are labelled by the gene that is considered most likely to carry the causative SNP. Where the metabolic trait is consistent with a nearby gene's function, details are provided in the column labelled 'Relationship between gene function and the associated metabolic traits'. Overlaps with associations from other GWAS studies are highlighted in bold (R 2 . 0.8, details are in Supplementary Table 6 ). 1 , Metabolic traits that are associated with the SNP at the corresponding locus. Further information and full bibliographic references are presented in Supplementary 
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biochemical function of the associated metabolic traits identified here may support a possible role in heart disease. For example, NAT8 may be linked to CKD via ornithine acetylation (see above). KLKB1, encoding kallikrein B plasma (Fletcher factor) 1, controls blood pressure via the bradykinin pathway. In this study, a genetic variant in KLKB1 was associated with bradykinin concentrations and we also confirmed the expected directional association of bradykinin with hypertension in both our studies (P KORA 5 1.7 3 10
29
, P TwinsUK 5 0.0495, with the covariates age and gender). ABO and ALPL associated with FAaP, and we therefore speculate that genetically determined differences in FAaP and resulting blood-coagulation properties may be the basis of these associations with CAD. Furthermore, our associations indicate that the role of FAaP as a biomarker for acute myocardial infarction, and the combined additive genetic effect of the ABO, ALPL and FUT2 loci ( Supplementary Fig. 4 ) on CAD risk, should be investigated in greater detail.
New biological and functional insights
Genome-wide association studies merely uncover statistically significant associations, and can therefore only generate biological hypotheses. Although providing experimental validation of all associations is beyond the scope of a single study, we nevertheless attempted to show that, in principle, validation is possible. The association of SNP rs7094971 in solute carrier family 16, member 9 ), there was no significant uptake, indicating that MCT9 does not mediate carnitine uptake (data not shown). Because some previously characterized monocarboxylic acid transporters are proton-coupled 37 , the experiments were conducted at both pH out 7.4 and pH out 5.5, but no significant difference was observed (a and data not shown). In agreement with this, external unlabelled carnitine was unable to trans-stimulate . The 37 genetically determined metabotypes (GDMs) that we have reported here explain a highly relevant amount of the total variation in the studied population and therefore contribute substantially to the genetic part of human metabolic individuality. a, GDMs are shown colourcoded by general metabolic pathways, together with selected associated metabolic traits, highlighting the relationship between gene function and the associated metabolic trait (see column 4 in Table 1 ). b, GDMs colour-coded by overlap with associations in previous GWAS with disease (red), intermediate risk factors for disease (yellow) and other traits (green). Locus overlap is defined here by the lead SNP reported in the national human genome research institute (NHGRI) GWAS catalogue being highly correlated (R 2 $ 0.8) with the most associated SNP in the metabolomics scan (see column 5 in Table 1 and Supplementary Table 7 ). Note that the overlap between the metabolomics loci and the loci reported by the NHGRI GWAS catalogue is highly significant when compared to a draw of 37 randomly selected SNPs with similar properties (P , 3 3 10
26
, see Methods).
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(SLC16A9, also known as MCT9) with carnitine indicated that this metabolite is the substrate of this hitherto uncharacterized monocarboxylic acid transporter. We therefore tested [ 3 H]-carnitine uptake by SLC16A9-expressing Xenopus oocytes. As shown in Fig. 2 , our data show that SLC16A9 is a pH-independent carnitine efflux transporter, possibly responsible for carnitine efflux from absorptive epithelia into the blood.
Another prominent example is the highly significant association of increased urate levels, and their clinical complication of gout, with variants in the SLC2A9 gene 22 . The association between SLC2A9 variants and urate levels was also observed here. Although it was previously annotated as a glucose transporter, SLC2A9 was later shown 23 to encode a high-capacity urate transporter. Similar characterization experiments by specialists in the related fields should be motivated and guided by our association data. Among the 37 GDMs reported here, we suggest that the associations with coarsely-characterized genes for enzymes and transporters that are known disease-risk loci may warrant further experimental investigation, for instance in experiments using isotope-labelled derivatives of the associated metabolites reported here as putative target substrates. We deem NAT8 to be a prime candidate for such a study.
Pharmacogenomics
Using the pharmacogenomics knowledge base 24 , we identified six GDMs as being previously associated with toxicity or adverse reactions to medication. Noteworthy are polymorphisms in the NAT2 and CYP4A loci that associated with toxicities to docetaxel and thalidomide treatment 25 ; the UGT1A locus with irinotecan toxicity 26 , SLC2A9 with the IC 50 of etoposide 27 , SLC22A1 with metformin pharmacokinetics 28, 29 and SLCO1B1 with statin-induced myopathy 30 . In all cases, our associations with metabolic traits at these loci provide a possible novel biochemical basis for the genotype-dependent reaction to drug treatment, such as the association of SLCO1B1 with a series of fatty acids, including tetradecanedioate and hexadecanedioate. This information can be used to support the redesign of the respective drug molecules to avoid adverse reactions. Moreover, systematic inclusion of biochemically relevant GDMs as candidate SNPs during drug trials may permit early identification of potentially adverse pharmacogenetic effects. This applies specifically to AKR1C, which is a novel target of jasmonates in cancer cells 31 . We reported a GDM associated with AKR1C which has a large effect-size on androgen metabolism. The influence of SNP rs2518049 in AKR1C on the efficiency and potential side effects of jasmonates should therefore be assessed in future clinical trials.
Discussion
Owing to their large effect-size and high explained variance, the 37 GDMs reported in this study indicate key genetic loci underpinning differences in human metabolism. Inclusion of these genetic variants in the statistical analysis of pre-clinical and clinical studies may facilitate identification of genotype-dependent outcomes, such as disease complications and adverse drug reactions. In two cases, we could establish a direct functional link, supported by both our studies, between a genetic variant, an intermediate metabolic trait and a disease-relevant endpoint: KLKB1 with bradykinin and hypertension, and NAT8 with N-acetylornithine and eGFR. We note that by discussing only associations that are supported by two independent studies at genome-wide significance, we have chosen to take a very conservative approach. On the basis of QQ-plots and coarse assumptions, we estimate that more than 500 loci with signals of association below that conservative threshold may be confirmed as GDMs in more highly powered studies in the future. Technically, it is of note that by using a single study to profile 2,820 individuals metabolically, using only 100 ml of blood serum, we replicated in this study a wide series of findings from previous large GWAS with quantitative traits, including serum levels of fasting glucose 12 , bilirubin 32, 33 , urate 34 and dehydroisoandrosterone sulphate 35 . Our study shows how GWAS with intermediate traits that are close to the underlying biological processes can provide new functional insights into associations from GWAS with the endpoints of complex chronic disease and drug toxicity. Future GWAS that combine multiple 'omics' technologies in a single study, including transcriptomics, proteomics, metabolomics and recent technologies for determining epigenetic modifications on a genome-wide scale, are likely to be the next big step towards a full understanding of the interaction between genetic predispositions and environmental factors in the development of complex chronic diseases, their diagnosis, prevention and safe and efficient therapy.
METHODS SUMMARY
The full Methods section provides information about study design, genetic and metabolic data collection, and data analysis. 
METHODS
Study populations. The KORA S4 survey, an independent population-based sample from the general population living in the region of Augsburg, southern Germany, was conducted in 199922001. The study design and standardized examinations of the survey (4,261 participants, response 67%) have been described in detail (ref 39 and references therein). A total of 3,080 subjects participated in a follow-up examination, KORA F4, in 200622008, comprising individuals who, at that time, were aged 32-81 years. The TwinsUK cohort is a British adult-twin registry in the age range 8-102 years and 84% are female. The samples used in this study are aged 23-85 (mean age 48 years) and 97% are female. These unselected twins were recruited from the general population through national media campaigns and were shown to be comparable to age-matched population singletons in terms of disease-related and lifestyle characteristics 40 .
In both studies, written informed consent has been given by all participants and the studies have been approved by the local ethics committees (Bayerische Landesärztekammer for KORA and Guy's and St. Thomas' Hospital Ethics Committee for TwinsUK). Blood sampling. Blood samples for metabolic analysis and DNA extraction from KORA were collected between 2006 and 2008 as part of the KORA F4 follow-up. To avoid variation due to circadian rhythm, blood was drawn in the morning between 08:00 and 10:30 after a period of at least 10 h overnight fasting. Material was drawn into serum gel tubes, gently inverted twice and then allowed to rest for 30 min at room temperature (18225 uC) to obtain complete coagulation. The material was then centrifuged for 10 min (2,750g at 15 uC). Serum was divided into aliquots and kept for a maximum of 6 h at 4 uC, after which it was frozen at 280 uC until analysis. For the TwinsUK study, blood samples were taken after at least 6 h of fasting. The samples were immediately inverted three times, followed by 40 min of resting at 4 uC to obtain complete coagulation. The samples were then centrifuged for 10 min at 2,000g. Serum was removed from the centrifuged brown-topped tubes as the top, yellow, translucent layer of liquid. Four aliquots of 1.5 ml were placed into skirted microcentrifuge tubes and then stored at 245 uC until sampling. Metabolomics measurements. Metabolon, a commercial supplier of metabolic analyses, developed a platform that integrates the chemical analysis, including identification and relative quantification, data-reduction and quality-assurance components of the process. The analytical platform incorporates two separate ultrahigh-performance liquid chromatography/tandem mass spectrometry (UHPLC/MS/MS2) injections and one gas chromatography/mass spectrometry (GC/MS) injection per sample. The UHPLC injections were optimized for basic and acidic species. A total of 295 metabolites were measured, spanning several relevant classes (amino acids, acylcarnitines, sphingomyelins, glycerophospholipids, carbohydrates, vitamins, lipids, nucleotides, peptides, xenobiotics and steroids; a full list of metabolites is given in Supplementary Table 1 ). The detection of the entire panel was carried out with 24 min of instrument analysis time (two injections at 12 min each), while maintaining low median process variability (,12% across all compounds). The resulting MS/MS 2 data were searched against a standard library generated by Metabolon that included retention time, molecular mass to charge ratio (m/z), preferred adducts and in-source fragments as well as their associated MS/MS spectra for all molecules in the library. The library allowed for the identification of the experimentally detected molecules on the basis of a multiparameter match without the need for additional analyses. Metabolon has shown in a recent publication that their integrated platform enabled the high-throughput collection and relative quantitative analysis of analytical data and identified a large number and broad spectrum of molecules with a high degree of confidence 5 . The Metabolon platform has, among other studies, been successfully applied in the analysis of the adult human plasma metabolome 41 and the identification of sarcosine as a biomarker for prostate cancer 42 . Quality control of metabolomics data. For this study we measured the Metabolon panel in human blood from 1,768 individuals of the KORA cohort and in 1,052 individuals of the TwinsUK cohort. Quality control data (relative standard deviation, upper and lower 95% confidence interval and minimum and maximum observed values in quality control samples) are reported in Supplementary Table 1 . To avoid spurious false-positive associations due to small sample sizes, only metabolic traits with at least 300 non-missing values were included, and data points of metabolic traits that lay more than three standard deviations off the mean were excluded by setting them to 'missing' in the analysis: 276 of 295 available metabolites and 37,179 metabolite ratios satisfied this criterion in KORA, resulting in a total of 37,455 metabolic traits. For the TwinsUK study, identical selection criteria for metabolic traits were used, resulting in 258 metabolites and 32,499 metabolite ratios, and a total of 32,757 metabolic traits. Genotyping and imputation. For all individuals profiled from the KORA study, genome-wide SNP data were already available. GWAS data of KORA and TwinsUK have been used and described extensively in the past, in the context of numerous GWAS and meta-analyses 3, 34, 43 . We therefore summarize only the essential details here. Genotyping of the KORA F4 population was carried out using the Affymetrix GeneChip array 6.0. Genotypes were determined using the Birdseed2 clustering algorithm. For quality assurance, we applied the criteria of call rate . 95% and P(Hardy-Weinberg) . 10 26 as filters for SNP quality: 655,658 autosomal SNPs satisfied these criteria. These genotyped SNPs were used for genome-wide analysis of the metabolic traits. For selection of the best-associated SNP within a region in a meta-analysis of KORA and TwinsUK, we used genotyped SNPs as well as dosages of imputed SNPs. In KORA F4, imputation was done using IMPUTE v0.4.2 (ref. 44 ) based on HapMap2 (see below).
Genotyping of the TwinsUK data set was done with a combination of Illumina arrays (HumanHap300, HumanHap610Q, 1M-Duo and 1.2MDuo 1M) 45, 46 . We pooled the normalized intensity data for each of the three arrays separately (with 1M-Duo and 1.2MDuo 1M pooled together). For each data set, we used the Illluminus calling algorithm 47 to assign genotypes in the pooled data. No calls were assigned if an individual's most likely genotype was called with a posterior probability threshold of ,0.95. Validation of pooling was achieved via a visual inspection of 100 random, shared SNPs for overt batch effects. Finally, intensity cluster plots of significant SNPs were visually inspected for over-dispersionbiased no calling, and/or erroneous genotype assignment. SNPs showing any of these characteristics were discarded.
We applied similar exclusion criteria to each of the three data sets separately. Exclusion criteria for samples were: (1) sample call rate ,98%; (2) heterozygosity across all SNPs $ 2 s.d. from the sample mean; (3) evidence of non-European ancestry as assessed by principle-component-analysis comparison with HapMap3 populations; (4) observed pairwise identity-by-descent (IBD) probabilities indicative of sample identity errors. We corrected misclassified monozygotic and dizygotic twins on the basis of IBD probabilities. Exclusion criteria for SNPs were: (1) HardyWeinberg P value ,10
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, assessed in a set of unrelated samples; (2) minor allele frequency (MAF) ,1%, assessed in a set of unrelated samples; (3) SNP call rate ,97% (SNPs with MAF $ 5%) or ,99% (for 1% # MAF , 5%).
Alleles of all three data sets were aligned to HapMap2 or HapMap3 forwardstrand alleles. Before merging, we performed pairwise comparison among the three data sets and further excluded SNPs and samples to avoid spurious genotyping effects, identified as follows: (1) concordance at duplicate samples ,1%; (2) concordance at duplicate SNPs ,1%; (3) visual inspection of QQ-plots for logistic regression applied to all pairwise data-set comparisons; (4) HardyWeinberg P value , 10 26 , assessed in a set of unrelated samples; (5) observed pairwise IBD probabilities indicative of sample identity errors. We then merged the three data sets, keeping individuals typed at the largest number of SNPs when an individual was typed at two different arrays. The merged data set consists of 5,654 individuals (2,040 from the HumanHap300, 3,461 from the HumanHap610Q and 153 from the HumanHap1M and 1.M arrays), and up to 874,733 SNPs depending on the data set (HumanHap300: 303,940, HumanHap610Q: 553,487, HumanHap1M and 1.M: 874,733). Imputation was performed using the IMPUTE software package (v2) 44 , using two reference panels, P0 (HapMap2, rel 22, combined CEU1YRI1ASN panels) and P1 (610k1, including the combined HumanHap610k and 1M reduced to 610k SNP content). The analysis of this study used 534,665 autosomal SNPs (basically 610K SNPs extracted from the final merged data set). Statistical analyses. The primary association testing was carried out using linear regressions on all metabolite concentrations and all possible ratios of metabolite concentrations. This was motivated by our previous observation 4, 8 that the use of ratios may lead to a strong reduction in the overall trait variance. A test of normality showed that in 29,338 cases, the log-transformed ratio distribution was significantly better represented by a normal distribution than when untransformed ratios were used. In 5,145 cases, the untransformed distribution was closer to a normal distribution. For concentrations, 149 were closer to a lognormal distribution and 124 were better represented by a normal distribution. On the basis of this observation, and also for sake of simplicity, we decided to logtransform all metabolites and their ratios. We used P-gain statistics 4, 8 to quantify the decrease in P value for the association with the ratio compared to the P values of the two corresponding concentrations. A high P-gain (more than 250) indicates that two metabolites are likely to be functionally linked in a metabolic pathway that has an impact on the associating genotype KORA and TwinsUK are population-based studies. They comprise only individuals who are not displaying any severe clinical symptoms at the time of sampling. Therefore, disease state was not considered as a confounding factor in the statistical analysis. In KORA, the software PLINK (version 1.06) 48 and SNPTEST was used with age and gender as covariates. To account for the family structure in the TwinsUK study, we used variance components applied to a score test implemented in the software Merlin 49 .
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